Monographie - Nivolumab

Ultimele actualizari :
05/12/2025

Nivolumab

Denumirea comerciala

Trade names are indicative and excipients composition can be different depending on the country and manufacturers

Opdivo

Argentina, Australia, Belgia, Brazilia, Chilli, Elvetia, Finlanda, Franta, Germania, Irlanda, Italia, Japonia, Luxemburg, Marea Britanie, Mexic, Norvegia, Peru, Romania, Spania, Suedia, Ungaria

Bibliografie : Nivolumab

	tip	publicare
2296	Laborator	Témocilline (Negaban®) - Résumé des caractéristiques du produit Eumedica 2017
4025	poster	Vieillard V, Bardo P, Akrout W, Le Guyader G, Astier A, Paul M. Stabilité physico-chimique de solutions de Nivolumab à 1 mois. SFPO Congress 2017 - Nantes 2017
4505	ziar	Le Guyader G, Vieillard V, Mouraud S, Do B, Marabelle A, Paul M. Stability of nivolumab in its original vials after opening and handing in normal saline bag for intravenous infusion. Eur J Cancer 2020 ; 135: 192-202.
4652	Laborator	Nivolumab (Opdivo®) - Summary of Product Characteristics Bristol Myers Squibb Pharmaceuticals 2022
4895	ziar	Fukudo M, Ishikawa R, Mishima K, Ono T, Matsumoto S, Tasaki Y. Real-World Nivolumab Wastage and Leftover Drug Stability Assessment to Facilitate Drug Vial for Cost Savings. JCO Oncology Practice 2020 ; 16, 10: e1134-e1142.

Mentions Légales